Cocrystal Pharma, Inc. announced a non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases for exploratory preclinical studies to evaluate the potential of Cocrystal’s 3CL protease inhibitors for the treatment of COVID-19.
[Cocrystal Pharma, Inc.]
